<DOC>
	<DOCNO>NCT02230995</DOCNO>
	<brief_summary>The purpose trial demonstrate bioequivalence newly develop fix dose combination ( FDC ) tablet contain empagliflozin metformin extend release compare free combination empagliflozin metformin extend release fed condition .</brief_summary>
	<brief_title>Bioequivalence Fixed Dose Combination Tablet Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject Exclusion criterion : Any relevant deviation healthy condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>